drugset / Trial / NCT01976507

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

NCT01976507

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.

Timeline

Start
2013-10
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 75 mg
Subject Dabigatran etexilate Unknown 150 mg